Search results
Results from the WOW.Com Content Network
Survival rates for treated esthesioneuroblastoma are best for surgery with radiotherapy (65%), then for radiotherapy and chemotherapy (51%), just surgery (48%), surgery, radiotherapy and chemotherapy (47%) and finally just radiotherapy (37%). [14] From the literature, radiotherapy and surgery seem to boast the best outcome for patients.
By data from England, the overall 5-year survival rate of neuroblastoma is 67%. [59] Between 20% and 50% of high-risk cases do not respond adequately to induction high-dose chemotherapy and are progressive or refractory. [60] [61] Relapse after completion of frontline therapy is also common. Further treatment is available in phase I and phase ...
In the United States during 2013–2017, the age-adjusted mortality rate for all types of cancer was 189.5/100,000 for males, and 135.7/100,000 for females. [1] Below is an incomplete list of age-adjusted mortality rates for different types of cancer in the United States from the Surveillance, Epidemiology, and End Results program.
Small cell lung cancer has a five-year survival rate of 4% according to Cancer Centers of America's Website. [5] The American Cancer Society reports 5-year relative survival rates of over 70% for women with stage 0-III breast cancer with a 5-year relative survival rate close to 100% for women with stage 0 or stage I breast cancer.
This is an accepted version of this page This is the latest accepted revision, reviewed on 3 February 2025. Neoplasm in the brain Medical condition Brain tumor Other names Intracranial neoplasm, brain tumour, brain cancer Brain metastasis in the right cerebral hemisphere from lung cancer, shown on magnetic resonance imaging Specialty Neurosurgery, neuro-oncology Symptoms Vary depending on the ...
Five-year survival rates can be used to compare the effectiveness of treatments. Use of five-year survival statistics is more useful in aggressive diseases that have a shorter life expectancy following diagnosis, such as lung cancer , and less useful in cases with a long life expectancy, such as prostate cancer .
In 2008, the Dana-Farber Cancer Institute in Boston reported two-year overall survival of 53% and event-free survival of 70% (median age at diagnosis of 26 months). [7] In 2013, the Medical University of Vienna reported five-year overall survival of 100%, and event-free survival of 89% (median age at diagnosis of 24 months).
Prevalence of olfactory dysfunction in the general US population was assessed by questionnaire and examination in a national health survey in 2012–2014. [31] Among over a thousand persons aged 40 years and older, 12.0% reported a problem with smell in the past 12 months and 12.4% had olfactory dysfunction on examination.